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Objectives: To assess the risk of medication errors in
subjects with renal impairment (defined as an
estimated glomerular filtration rate (eGFR) ≤40 ml/min/
1.73 m2) and the effectiveness of automatic eGFR ≤40-
alerts relayed to community pharmacists.
Design: Clinical survey.
Setting: The city of Zwolle, The Netherlands, in a
primary care setting including 22 community
pharmacists and 65 general practitioners.
Participants: All adults who underwent ambulatory
creatine measurements which triggered an eGFR
≤40-alert.
Primary and secondary outcome measures: The
total number of ambulatory subjects with an eGFR
≤40-alert during the study period of 1 year and the
number of medication errors related to renal
impairment. The type and number of proposed drug
adjustments recommended by the community
pharmacist and acceptance rate by the prescribing
physicians. Classification of all medication errors on
their potential to cause an adverse drug event (ADE)
and the actual occurrence of ADEs (limited to those
identified through hospital record reviews) 1 year after
the introduction of the alerts.
Results: Creatine measurements were performed in
25 929 adults. An eGFR ≤40-alert was indicated for
5.3% (n=1369). This group had a median (IQR) age of
78 (69, 84) years, and in 73% polypharmacy (≥5
drugs) was present. In 15% (n=211) of these subjects,
a medication error was detected. The proportion of
errors increased with age. Pharmacists recommended
342 medication adjustments, mainly concerning
diuretics (22%) and antibiotics (21%). The physicians’
acceptance rate was 66%. Of all the medication errors,
88% were regarded as potential ADEs, with most
classified as significant or serious. At follow-up, the
ADE risk (n=40) appeared highest when the proposed
medication adjustments were not implemented
(38% vs 6%).
Conclusions: The introduction of automatic eGFR-
alerts identified a considerable number of subjects who
ARTICLE SUMMARY
Article focus
▪ To evaluate the number of subjects with at risk for
medication errors due to renal impairment
(defined as estimated glomerular filtration rate
(eGFR) ≤40 ml/min/m2) in a primary care setting.
▪ To assess the risk of medication errors in subjects
with renal impairment.
▪ To evaluate the effectiveness of generating auto-
matic eGFR ≤40-alerts and medication reviews
involving community pharmacists.
Key messages
▪ Providing renal laboratory data to pharmacists in a
primary care setting revealed that there were a
considerable number of subjects at increased risk
for adverse drug events (ADEs) due to renal
impairment.
▪ The issuance of eGFR alerts allowed community
pharmacists to provide valuable medication adjust-
ment recommendations to the prescribing physi-
cians, with a good acceptance rate.
▪ The implementation of this simple protocol could
identify many potential ADEs, thereby substantially
reducing the risks of unnecessary iatrogenic
damage in subjects with impaired renal function.
Strengths and limitations of this study
▪ Implementation of this protocol in clinical practice
is possible in various healthcare settings.
▪ Increased collaboration with community pharma-
cists improved healthcare safety and awareness of
medication errors related to renal function impair-
ment in primary care.
▪ Extending the availability of laboratory renal data
which were not formerly shared is relatively
straightforward with minimal expense.
▪ Effect of eGFR alerts on the incidence of ADEs
could not be measured.
▪ Study design does not allow either the determin-
ation of individual healthcare effects or an overall
cost–benefit analysis of this healthcare safety
strategy.
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are at risk for ADEs due to renal impairment in an ambulatory
setting. The nationwide implementation of this simple protocol could
identify many potential ADEs, thereby substantially reducing
iatrogenic complications in subjects with impaired renal function.
INTRODUCTION
Safe medication management is an important health-
care topic, as medication errors are a signiﬁcant source
of iatrogenic injury to patients.1–7 Injuries resulting from
such errors are known as adverse drug events (ADEs).
Various factors are associated with ADEs, including
patient characteristics, lack of medication monitoring
and prescription errors.4–6 8 Studies on medication-
related hospital admissions estimate that 21–91% of
admissions were potentially preventable.1 6 9 10
Important patient determinants for ADEs are increasing
age, female gender, polypharmacy, non-compliance and
comorbidities such as cognitive dysfunction or renal
impairment.1–4 7 8 10
Renal impairment is a well-known risk factor for
ADEs, but it often remains unrecognised by physicians
and pharmacists.11–14 Even in high-risk patients such as
the elderly and those with diabetics, healthcare workers
are not always sufﬁciently alert.15–17 Various studies
reported considerable dosing difﬁculties and subsequent
medication errors in patients with renal impair-
ment.10 12 17–19 Therefore, intensiﬁed collaboration
between healthcare workers (such as general practi-
tioners (GPs), pharmacists and nephrologists) is
recommended with exchange of relevant patient infor-
mation (medical history and comorbidities) and more
effective use of routinely collected data from electronic
patient records such as laboratory results relating to
renal function.2 6 20–23
In this 1-year observational study, we aimed to evaluate
the number of subjects at risk for medication errors due
to renal impairment (deﬁned as an estimated glomeru-
lar ﬁltration rate (eGFR) ≤40 ml/min/1.73 m2) and the
effectiveness of providing automatically generated eGFR
≤40-alerts towards community pharmacists in a shared
pharmaceutical care model. In addition, we classiﬁed all
medication errors for their potential to cause ADEs and
evaluated the actual number of ADEs in those with a
medication error after a period of 1 year.
MATERIALS AND METHODS
Setting
This study was conducted in Zwolle, which is a city in
the north of the Netherlands with a population of more
than 89 000 adults.24 All of the primary care pharmacies
(n=11) and the general practices (n=24) participated in
this study. Their characteristics are shown in table 1.
Dutch patients are generally registered at one single
pharmacy and GP practice, which promotes continuity
of care and reliable information regarding each indivi-
dual’s medication use. Secondary care in this region is
delivered by the Isala Clinics, a 1000+bed teaching hos-
pital in Zwolle. All standard laboratory investigations
requested in both primary and secondary care are
Table 1 Characteristics of participating pharmacists and GPs and their practices
Characteristics Pharmacists GPs
Participants
Number (%) 22 (100) 65 (100)
Sex, n (%)
Male 9 (40) 42 (65)
Female 13 (60) 23 (35)
Years in practice, n (%)
0–10 10 (45) 25 (39)
11–20 9 (41) 15 (23)
21–30 0 (0) 21 (32)
>30 3 (14) 4 (6)
Position in practice, n (%)
( Joint) owner 6 (27) 45 (70)
Employee 16 (73) 20 (30)
Practice
Number (%) 11 (100) 24 (100)
Practice type, n (%)
Independent 9 (80) –
Chain 2 (20) –
Overall number of patients, n 114.033 117.147
Practice size, median (IQR) 10 000 (7 000, 14 000) 3426 (2691, 6586)
Prescription system, n (%)
Computer based 11 (100) 24 (100)
GP, general practitioner.
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performed in one laboratory, which uses a single elec-
tronic system for data handling.
Design and case finding
This prospective observational study was conducted
between 1 February 2009 and 31 January 2010. During
this period, all consecutive adults in whom a serum cre-
atine was measured in the ambulatory setting and who
had an eGFR at or below the cut-off point of 40 ml/
min/1.73 m2 were identiﬁed, irrespective of the reason
for laboratory testing. This threshold was based on
guidelines advising dosage adjustment in renal impair-
ment25 26 and also chosen from a practical point of view.
A higher cut-off point of 50–60 ml/min/1.73 m2 was
expected to exceed an acceptable workload, and the
generation of many alarms induces the risk of ignoring
and overriding alerts. Each week, the laboratory auto-
matically generated a report for any ambulatory patients
with an eGFR ≤40 ml/min/1.73 m2 for the pharmacists.
Study protocol
A predeﬁned protocol was followed after the pharmacist
received a report on an eGFR ≤40 ml/min/1.73 m2
(ﬁgure 1). First, the patients’ pharmacist checked the
actual medication regimen for current errors related to
renal impairment. The numbers and types of errors
were registered. Medication errors were based on Dutch
Pharmacists’ guidelines including ‘the National
Formulary on drug prescribing in renal impairment’
and the ‘National Shared Care Guidelines on Chronic
Kidney Disease (CKD)’.25 26 Second, the pharmacist
alerted the prescribing physician (GP or clinician) on
the low eGFR and, if appropriate, an adjusted medica-
tion regimen was recommended. Pharmacists contacted
prescribing physicians by telephone or (if unreachable)
by email. Finally, an alert warning for a low eGFR (eGFR
≤40-alert) was activated in the patient’s pharmacy
record. This eGFR ≤40-alert then appeared with every
future new prescription. After this ﬁrst laboratory notiﬁ-
cation, follow-up eGFR results were also reported to the
pharmacists. When an eGFR recovered well beyond the
cut-off value during follow-up (speciﬁed as an
eGFR>50 ml/min/1.73 m2), the eGFR ≤40-alert was
removed from the pharmacy record.
The study was approved by the local medical ethics
committee and conducted in accordance with the guide-
lines of the Declaration of Helsinki. All pharmacists and
GPs informed their patients about the study through
ﬂyers, issued both at the pharmacies and at the GP prac-
tices. The patient folder and the Isala Clinics website
Figure 1 Flow chart summarising study method and selection of study population.
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also contained information about the stepwise eGFR
≤40-alert protocol, the sharing of laboratory data and
medication monitoring. The study had an opt-out
policy; therefore, subjects who did not wish to partici-
pate in this pharmacovigilance study were excluded
from the weekly reporting. It should be emphasised that
the ﬁnal decision about making any medication changes
after an alert (and informing the patient) was consid-
ered to be the responsibility of the prescribing
physician.
Definitions and calculations
Serum creatine was measured with an enzymatic essay
(Modular, Roche, Mannheim, Germany), and eGFR was
calculated with the enzymatic MDRD formula.27 The
only medications included were those prescribed by
healthcare professionals, and topical or over-the-counter
products were excluded. Actual medication use was
assessed by documenting all current prescriptions
according to the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system28 at the moment of the ﬁrst
eGFR ≤40-alert. Polypharmacy was deﬁned as the
chronic (>1 year) use of ≥5 drugs.
Data collection
For all identiﬁed subjects with an eGFR ≤40-alert, demo-
graphics and medication information were collected.
Any medication adjustment recommendations were
recorded, which included the patient’s medical record
number, the pharmacist, the type and daily dose of the
medication, and the prescribing physician (GP or clin-
ician). The physician’s response to the pharmacist’s rec-
ommendation was also recorded. Finally, the amount of
time the pharmacists spent on every eGFR ≤40-alert was
documented.
Classification and tracking of (potential) ADEs
To evaluate the impact of eGFR≤40-alerts, two pharma-
cists (EVvdP and KJB) independently evaluated all medi-
cation errors on the potential to cause an ADE (deﬁned
as a potential ADE (pADE)). They received a database
that was anonymised by an investigator not involved in
the eGFR-alert processing (HJ). A methodology was
developed for classiﬁcation of medication errors and
(p)ADEs.29 They judged and classiﬁed the theoretical
severity of the medication error, yielding a score of 0–4
(0=drug error without signiﬁcant harm, 1=potentially
signiﬁcant, 2=potentially serious, 3=potentially life threa-
tening, 4=potentially fatal) (table 2). To reach a consen-
sus, all discrepant ratings were discussed with both
pharmacists and two nephrologists (HJGB and HJ).
Examples of pADE classiﬁcations are listed in table 2.
The best assessment of the number of ADEs proved to
be from the documentation on ADEs in the hospital
records.30 Therefore, 1 year after the end of the study,
the hospital records of all subjects in whom a medica-
tion error was detected were reviewed. This review was
performed by two nephrologists (HJ and HJGB) who
independently checked the occurrence of ADEs. ADEs
were based on admission and discharge diagnosis in the
patients’ medical records. The relationship of the ADE
with the ‘suspected’ agent was double-checked by evalu-
ating whether the medication regimen at admission in
the hospital record matched with the pharmacy record
at the date of admission. After a review of the hospital
records, HJ and HJGB discussed their ﬁndings for reach-
ing consensus.
Data analysis
The main outcome measures were the incidence of
eGFR ≤40-alerts, the number and types of medication
Table 2 Categories of potential adverse drug events according to severity
Score Potential severity Examples
0 Drug error without potential
harm
Not applicable
1 Significant Gastrointestinal complaints
Therapeutically ineffective dose according to eGFR
Mild neurological effects (e.g. motoric dysfunction)
Hepatic dysfunction
Any significant event identified by patient which does not require change in
therapy
2 Serious Hypoglycaemia
Nephrotoxicity or increased risk nephrolithiasis
Electrolyte disturbances (e.g. hyperpotassiemia)
Altered mental status due to sedation
Myopathy or rhabdomyolysis
Gastrointestinal bleed
3 Life threatening Lactic acidosis
Cardiac arrhythmia
Decline in mental status with risk of falling
Respiratory failure requiring intubation (e.g. bronchospasms)
4 Fatal Death
4 Joosten H, Drion I, Boogerd KJ, et al. BMJ Open 2013;3:e002068. doi:10.1136/bmjopen-2012-002068
Primary care pharmacists supporting drug safety in renal impairment
group.bmj.com on February 28, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
errors and the number and types of medication adjust-
ment proposals. Secondary outcome measures were the
time required for pharmacists to process the eGFR
≤40-alerts, the adherence of physicians to the proposed
adjustments, risk factors for medication errors and the
severity of medication errors. In addition, after 1 year of
follow-up, we checked the incidence of ADEs in subjects
in whom a medication error was detected. Statistical ana-
lysis was performed with SPSS V.16.0 (SPSS Inc.,
Chicago, Illinois, USA). Data are presented as the mean
and SD when normally distributed. Otherwise, the
median and (IQR) were used. For normally distributed
data, the differences in baseline characteristics were eval-
uated with the independent samples t test. For non-
parametric data, the Mann-Whitney U test was used.
Differences in distribution were calculated using the
χ2 tests.
RESULTS
Incidence of eGFR ≤40-alert and characteristics of the
study population
During the study period, 46 781 creatine measurements
were performed in 25 929 subjects. In 5.3% (n=1369) of
cases, an eGFR ≤40-alert was indicated. One patient indi-
cated no willingness to participate for privacy reasons,
leaving 1368 subjects for analysis (ﬁgure 1). Their charac-
teristics are summarised in table 3. Overall, 56% were
women, the median age was 78 (69, 84) years (distribu-
tion is shown in ﬁgure 2) and the median eGFR was 34
(27, 38) ml/min/1.73 m2. Overall, polypharmacy was
present in 73% (n=993) with a mean number of medica-
tions per patient of 7 (range 0–21). An overview of the
actual medication use in the study population (which
reﬂects comorbidities) according to the ATC classiﬁca-
tion is given in online supplementary appendix A.
Number and type of medication errors
Overall, 342 medication errors were detected in 211
patients with an eGFR ≤40-alert (15% of the study popu-
lation) (ﬁgure 1). The proportion of errors increased
with increasing age (ﬁgure 2). The types of medication
most commonly associated with errors were diuretics
(22%), antibiotics (21%) and antigout medications
(15%) (ﬁgure 3). The majority of these medications
(77%) were prescribed by GPs. An overview of the type
of medication errors that were identiﬁed by the pharma-
cists is given in ﬁgure 4.
Physicians’ compliance with medication adjustment
recommendations
Figure 5 gives an overview of the frequency and types of
medication adjustment recommendations. The most
common recommendations were ‘change dosage’
(55%), followed by ‘stop medication’ (24%). In 31%
(n=105), the proposal concerned a new prescription.
Physicians complied with the recommendation in 66%
(n=226) of cases. In 28% (n=96) of cases, the pharma-
cists’ advice was rejected and the medication regimen
remained unchanged. The main reasons for rejection
included already increased alertness with intensive moni-
toring by the prescribing physician (often being an
internist or nephrologist) and an inadequate response
to lower dosages in the past. The majority of rejected
recommendations included diuretics and renin–angio-
tensin–aldosterone system blockers like ACE inhibitors
and ARB drugs. In some cases, the recovery of renal
function was expected or underestimation of renal func-
tion was presumed, both of which were generally
checked with a 24 h creatine clearance. Overall, acutely
reduced eGFR did not account for an important subset
of the eGFR<40-alerts towards the community pharma-
cists (n=3). Notably, in 22 of the 96 cases, the medica-
tion was soon changed anyway, due to a further decrease
in the eGFR or the occurrence of an ADE. Therefore,
from the latter it seems plausible that with the eGFR
≤40-alert, the physician’s awareness of the risk for an
Table 3 Characteristics of the study population
Variable
Number of subjects, n (%) 1368 (100)
Demographics
Age (years), median (IQR) 78 (69, 84)
Male, n (%) 601 (44)
Diabetes, n (%) 346 (25)
Renal variables
eGFR (ml/min/1.73 m2), median (IQR) 34 (27, 38)




Number of drugs, median (IQR) 7 (4, 9)
Polypharmacy, n (%) 993 (73)
eGFR, estimated glomerular filtration rate.
Figure 2 Age distribution of study population and risk of
medication error per age category.
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ADE was triggered. Data on rejection or agreement
lacked in 6% (n=20) of cases.
Potential risk factors for medication errors in patients
with eGFR ≤40 alerts
Compared to the subjects without medication errors
(n=1157), subjects for whom medication adjustments
were recommended (n=211) were more often female
subjects (59% vs 41%, p=0.04) and had a lower eGFR
(median 34 (28, 38) versus 29 (2, 34) ml/min/1.73 m2,
p<0.001, respectively). Notably, the latter had higher
rates of polypharmacy (70% vs 89%, p<0.001, mean
number of medications 6.6 (3.8) vs 8.2 (3.5), p<0.001).
Effectiveness: pADEs and occurrence of ADEs after
follow-up
Overall, 88% (n=299) of the medication errors were
regarded as relevant pADEs (score>0). These were
mainly judged to be either signiﬁcant or serious. An
overview of the number and potential severity of pADEs
in the study population is given in ﬁgure 1.
Overall, 40 ADEs were identiﬁed in hospital records
within 1 year after the study period in the group of
Figure 3 Medication groups
associated with medication errors
related to renal impairment.
Figure 4 Type of medication
errors identified by the
pharmacists.
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subjects with medication errors, including two life-
threatening ADEs (bradycardia due to digoxin intoxica-
tion and acute kidney injury with lactic acidosis asso-
ciated with persistent metformin use). The number and
severity of ADEs are shown in ﬁgure 1. Importantly, the
ADE risk was higher in subjects whose medication
regimen remained unchanged (n=60) as compared to
subjects whose medication regimen was adjusted as
recommended by the pharmacist (n=139); 38% vs 6%,
respectively.
Effectiveness: workload and time investment of the
pharmacists
After receiving an eGFR ≤40-alert, the pharmacist
needed an average of 11 mins (range 5–13 mins) to
check an individual’s medication regimen for errors.
When taking into account the time needed for consult-
ation with the prescribing physician, pharmacists
required an average of 20 mins to process one
eGFR≤40-alert triggering a medication adjustment. All
pharmacists judged the time investment as feasible, par-
ticularly considering the fact that each pharmacy
received an average of only one alert per week.
Retrospectively, we evaluated the feasibility of different
thresholds for kidney function alerts by calculating the
number of low eGFR-alerts that would have been gener-
ated during the study period using different cut-offs for
renal impairment (<30, <50 and <60 ml/min/1.73 m2,
respectively, see online supplementary appendix B).
Overall, 904 eGFR≤40-alerts were activated in the
records of the participating pharmacies at the end of
the study period, as 16% (n=214) of the population died
and in 250 subjects, the most recent eGFR was at least
twice >50 ml/min/1.73 m2. Therefore, on average, every
primary care pharmacy had 82 patients with an activated
eGFR ≤40-alert. If we translate this to a standard Dutch
GP practice (±2300 patients), simple laboratory data
sharing identiﬁed approximately 23 patients per practice
who need drug adjustment(s) or extra alertness in medi-
cation management.
DISCUSSION
The main ﬁndings of this study were that an eGFR
≤40-alert was indicated in 5.3% of the adult population
of a Dutch city in whom a creatine measurement was
performed in an ambulatory setting and that in these
subjects 342 medication errors (mainly involving antibio-
tics and diuretics) were detected during the year follow-
ing the introduction of an automatic eGFR ≤40-alert
system. The majority of the medication errors were
regarded as relevant pADEs, necessitating medication
adjustments as recommended by the pharmacists.
Physicians complied in 66% of cases. ADE risk increases
with age, polypharmacy and in instances where the pro-
posed medication adjustments were initially rejected.
Overall, automatically generated low eGFR-alerts in
primary care seemed effective, easy to implement, and,
importantly, improve both the pharmacists’ and the phy-
sicians’ awareness of medication safety.
Comparison with other studies
Despite the fact that medications are usually both pre-
scribed and dispensed in the primary care setting, most
studies on (p)ADEs have been hospital based.3 9 10 We
aimed to study the incidence of (p)ADEs in a shared
pharmaceutical care model with a central role for com-
munity pharmacists. Three primary healthcare studies
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on this topic reported lower pharmacist drug proposal
rates (0.7–1.9%) than the 15% we found.31–33 These
studies were performed in a general population, while we
selected a high-risk population of subjects with renal
impairment. In line with our results, primary and ambula-
tory care studies evaluating pharmacists’ drug proposals in
vulnerable subgroups like the elderly or subjects with car-
diovascular risk factors also reported higher rates.12 17 34 35
Two recent studies, also concerning subjects with renal
impairment, identiﬁed problems related to inappropriate
prescribing in over 20% of patients.18 36
Patients with renal impairment are especially vulner-
able to medication errors.12 13 18 Various strategies to
improve drug safety in these patients have been studied,
such as educational wards rounds, immediate clinician–
pharmacist feedback or dose adjustment according to
renal function at hospital discharge.12 18 37–42 However,
despite the fact that most prescribing takes place in the
primary healthcare setting, the majority of the strategies
implemented so far have been tailored to hospital set-
tings and are therefore not suitable for primary care.
Others have demonstrated the effectiveness of ‘compu-
terised physician order entry’ and ‘clinical decision
support’ in reducing medication errors in case of renal
impairment.39–41 However, computerised drug prescrib-
ing alerts do not always guarantee a reduction of pre-
scribing errors,43 partly because such alerts are often
overridden or ignored by prescribing physicians.41 44–46
This phenomenon is also reﬂected in our data, as in
28% of cases pharmacist recommendations were
rejected by the prescribing physician.
A central role for community pharmacists in improving
medication safety in primary care has been recognised.
Many pharmacists are gradually extending their role as
integral members of the medical team around the patient,
thereby taking an important position in a shared care
environment.21 47 48 This has not only been induced by
legislative issues,21 25 but also recommended in various
guidelines and studies to counteract problems associated
with multiple medication prescribers.20 26 32 48 This is
important in view of our ageing population in which
complex drug therapy will only increase, polypharmacy is
common and renal impairment widespread.49 50 A recent
review showed notable differences in ADE prevalence rates
by age groups, increasing from 5% for adults up to 16% for
the elderly.7 Therefore, in complex cases (as with renal
impairment), close collaboration between community
pharmacists and physicians is essential to prevent ADEs.
The alert method we have investigated here could be
a simple solution to address this.
Our strategy included three steps to reduce medica-
tion errors in patients with renal impairment. First, auto-
matic laboratory alerts were generated; second, these
alerts were linked to pharmacy data to judge the need
for drug adjustments; and third, pharmacists discussed
the recommended changes with physicians. Several
studies investigated the impact of the above steps. The
introduction of automatically generated laboratory alerts
had varied effects on the prescribing physician.41 51 52
Authors suggested that such passive alerts did not have
enough of an impact. There are limited data on the
effect of extending the alerts so that the community
pharmacist was also involved. Other studies showed that
when the pharmacy data were linked with the laboratory
renal data, the medication dosage could be beneﬁcially
adjusted.12 42 53 We aimed to optimise medication safety
in cases of renal impairment by combining the afore-
mentioned steps and tailored our strategy for application
in the primary care setting.
Implications for clinical practice
The estimated prevalence of both moderate (30–59 ml/
min/1.73 m2) and severe (15–29 ml/min/1.73 m2) renal
insufﬁciency in the adult American and Dutch popula-
tion is 4.5% and 5.3%, respectively.26 54 Therefore, the
number of subjects potentially susceptible to related
medication errors is substantial. If we compile our
pADE-rate towards nationwide ﬁgures (based on
12 500 000 adults in the Netherlands), our type of data
sharing could intercept more than 40 000 potential
ADEs related to renal impairment each year. This would
undoubtedly increase healthcare safety with already
available data and (hopefully) decrease the costs of
ADE-related morbidities. Drug safety management
might be further improved by extending patient data
exchange towards other important parameters, such as
medication allergies, platelet counts, electrolyte concen-
trations, international normalised ratio, liver enzymes
and plasma drug levels.
Strengths and weaknesses of the study
Some limitations of this study have to be noted. First,
our study design does not allow the determination of
either the individual healthcare effects or the overall
cost–beneﬁts. This would necessitate a more complex
study design as was, for example, used in the population-
based randomised controlled renal drug alert effective-
ness trial of Bhardwaja et al36 or a ‘before and after’
design. However, participating GPs and pharmacists indi-
cated that the protocol improved their awareness of
medication errors related to renal function impairment.
Second, data on the incidence of ADEs before the start
of the study project were not available in our region;
therefore, a possible change in ADE incidence as a
result of our interventions cannot be determined.
Besides, the incidence of ADEs is most likely underesti-
mated due to underreporting, missed recognition and
lack of recording in daily clinical practice. Our study
also has several strengths. First, our intervention can be
easily implemented in various healthcare settings. We
simply extended the availability of laboratory renal data
which were not shared formerly. Second, physicians
valued the pharmacists’ involvement in improving
healthcare delivery. The acceptance percentage of the
pharmacists was fairly good (67%), as compared to pre-
vious studies (24–82%),17 32 34 37 51 and our prescription
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ratio between GPs and hospital-based physicians (77 :
23%) reﬂects the normal distribution of prescriptions in
the Netherlands (82 : 18%).55 However, to improve the
overall efﬁciency of the eGFR-alerts, variables inﬂuen-
cing physicians’ (non) adherence to pharmacists’ recom-
mendations (like type and duration of medication use)
should also be further studied. Third, the time invest-
ment was acceptable and costs were low. Finally, we
chose a safe but also feasible threshold for renal func-
tion alerts. However, as thresholds for dosage adjustment
vary between different guidelines, a higher cut-off of
≤50 or 60 ml/min/1.73 m2 or drug-speciﬁc thresholds
could be discussed.25 26 36 56 Besides, as the
Cockcroft-Gault (CG) formula is often used in pharma-
cokinetic studies and for drug dosing recommendations,
the implications of the use of renal function estimates,
like the MDRD equations for drug dosing, are under
debate. Several studies have compared drug dosing
recommendations based on the CG with those based on
the MDRD.57–59 In summary, the accuracy of the MDRD
seems comparable to the CG.57–59 On the basis of these
studies, in our opinion, the MDRD is a reasonable alter-
native to the CG for drug dosing. This is of importance,
especially since there is an increasing trend of clinical
laboratories reporting the MDRD along with serum cre-
atine, which is also recommended by national and inter-
national organisations. 26 60 Some guidelines advise a
higher cut-off point for dose adjustments (creatine clear-
ance 50–60 ml/min),11 61 but this was expected to result
in an amount of alerts exceeding an acceptable work-
load. Moreover, as the MDRD tends to underestimate
true GFR, we presumably already included subjects with
true GFR >40 ml/min.62
Conclusions and policy implications
The introduction of automatic renal function alerts in
the ambulatory care setting, with the involvement of
both GPs and community pharmacists, revealed that a
considerable part of the population is at risk for ADEs
due to impaired renal function. Extending the availabil-
ity of renal laboratory data to community pharmacists
resulted in their presenting the prescribing physicians
with a considerable number of medication adjustment
recommendations. We feel that nationwide implementa-
tion of this simple protocol could potentially identify
many pADEs and substantially reduce the risks of iatro-
genic damage in persons with decreased renal function.
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